Synonym
BBR-3576; BBR 3576; BBR3576; Topixantrone.
IUPAC/Chemical Name
5-((2-(Dimethylamino)ethyl)amino)-2-(2-((2-hydroxyethyl)amino)ethyl)indazolo(4,3-gh)isoquinolin-6(2H)-one
InChi Key
ZHAKYGFJVGCOAE-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H26N6O2/c1-26(2)10-8-24-16-3-4-17-19-18(16)21(29)14-5-6-23-13-15(14)20(19)25-27(17)11-7-22-9-12-28/h3-6,13,22,24,28H,7-12H2,1-2H3
SMILES Code
O=C1C2=C(C=NC=C2)C3=NN(CCNCCO)C4=C3C1=C(NCCN(C)C)C=C4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS#
156090-18-5 (Topixantrone free base))
Preparing Stock Solutions
The following data is based on the
product
molecular weight
394.48
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Marini A, Berbenni V, Bruni G, Cofrancesco P, Margheritis C, Orlandi A, Villa
M. Hydration, stability, and phase transformations of a new antitumor drug. J
Pharm Sci. 2004 Sep;93(9):2222-31. PubMed PMID: 15295783.
2: Mross K, Scheulen ME, Licht T, Unger C, Richly H, Stern AC, Kutz K, Camboni
MG, Barbieri P, Verdi E, Vincenzi B, Bernareggi A. Phase I clinical and
pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v.
every 4 weeks in patients with advanced solid tumors: a phase I study group trial
of the Central European Society of Anticancer-Drug Research (CESAR). Anticancer
Drugs. 2004 Jan;15(1):15-22. PubMed PMID: 15090738.
